Rationale and design for a pragmatic randomized trial to assess gene‐based prescribing for SSRIs in the treatment of depression

• Asıl Yazarlar: Lindsay J. Hines (Yazar), Russell A. Wilke (Yazar), Rachel Myers (Yazar), Carol A. Mathews (Yazar), Michelle Liu (Yazar), Jordan F. Baye (Yazar), Natasha Petry (Yazar), Emily J. Cicali (Yazar), Benjamin Q. Duong (Yazar), Erica Elwood (Yazar), Leslie Hulvershorn (Yazar), Khoa Nguyen (Yazar), Michelle Ramos (Yazar), Azita Sadeghpour (Yazar), R. Ryanne Wu (Yazar), Lloyda Williamson (Yazar), Kristin Wiisanen (Yazar), Deepak Voora (Yazar), Rajbir Singh (Yazar), Kathryn V. Blake (Yazar), James W. Murrough (Yazar), Simona Volpi (Yazar), Geoffrey S. Ginsburg (Yazar), Carol R. Horowitz (Yazar), Lori Orlando (Yazar), Hrishikesh Chakraborty (Yazar), Paul Dexter (Yazar), Julie A. Johnson (Yazar), Todd C. Skaar (Yazar), Larisa H. Cavallari (Yazar), Sara L. Van Driest (Yazar), Josh F. Peterson (Yazar), the IGNITE Pragmatic Trials Network (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Wiley, 2024-06-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Abstract Specific selective serotonin reuptake inhibitors (SSRIs) metabolism is strongly influenced by two pharmacogenes, CYP2D6 and CYP2C19. However, the effectiveness of prospectively using pharmacogenetic variants to select or dose SSRIs for depression is uncertain in routine clinical practice. T...